You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR ORTATAXEL


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for Ortataxel

Trial ID Title Status Sponsor Phase Summary
NCT00039156 ↗ BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma Unknown status Theradex Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have refractory non-Hodgkin's lymphoma.
NCT00039169 ↗ BAY 59-8862 in Treating Patients With Advanced Kidney Cancer Unknown status Theradex Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have advanced kidney cancer.
NCT00054314 ↗ BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have non-small cell lung cancer.
NCT00054314 ↗ BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer Completed Roswell Park Cancer Institute Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have non-small cell lung cancer.
NCT01989884 ↗ An Efficacy Study Of Ortataxel In Recurrent Glioblastoma Completed Mario Negri Institute for Pharmacological Research Phase 2 Italian Study On The Efficacy Of Ortataxel In Recurrent Glioblastoma
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Ortataxel

Condition Name

Condition Name for
Intervention Trials
Glioblastoma 1
Kidney Cancer 1
Lung Cancer 1
Lymphoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Lymphoma, Non-Hodgkin 1
Lymphoma 1
Glioblastoma 1
Lung Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ortataxel

Trials by Country

Trials by Country for
Location Trials
United States 18
Canada 3
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
New York 2
New Jersey 2
Louisiana 2
Wisconsin 2
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ortataxel

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 2
Unknown status 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ortataxel

Sponsor Name

Sponsor Name for
Sponsor Trials
Theradex 2
National Cancer Institute (NCI) 1
Roswell Park Cancer Institute 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 2
Other 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.